['thalassemia major']
['ruxolitinib']

        Inclusion Criteria:

          -  Patients with thalassemia on a regular and stable transfusion regimen (at least 2 RBC
             units within every 4-week interval for 24 weeks prior to Screening) and anticipated to
             receive the same transfusion regimen during the study.

          -  Patients with spleen enlargement at Screening, defined as spleen palpable below the
             costal margin and spleen volume of ≥ 450 cm3 as confirmed by MRI (or CT scan in
             applicable patients).

          -  Patients need to be on iron chelation treatment (deferoxamine or deferasirox) for at
             least four weeks prior to Screening

        Exclusion Criteria:

          -  Splenectomy prior to or planned during the study

          -  Active serious bacterial, mycobacterial, fungal, parasitic or viral infection which
             requires therapy (e.g., pneumonia, tuberculosis, systemic mycosis, herpes zoster)

          -  Hemoglobin <65 g/L (<4.0 mmol/L) at Screening

          -  Platelet count <75×109/L, absolute neutrophils count < 1.5×109/L at Screening.

          -  Estimated MDRD < 30 mL/min/1.73 m2 at Screening.

          -  ALT (SGPT) levels >5 times ULN at Screening.

          -  Hepatocellular disease such as hepatitis B (presence of HBs antigen), hepatitis C
             (presence of HCV RNA), liver cirrhosis.

          -  HIV positivity
      